13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study has two stages and the aims are as follows:
Aim 1:
In Stage 1 of this study, the investigators aim to recruit first-time diagnosed lymphoma
patients, to understand the changes of metabolites before and after treatment, and to
evaluate the ability of hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization
(DNP) magnetic resonance spectroscopy (MRS) for detecting early treatment response in these
patients.
The pre-treatment metabolic imaging biomarker levels will be compared to the followings:
1. Post-treatment metabolites from 13C-pyruvate DNP MRS after the first week of
chemotherapy
2. Interval change in tumor size
3. ADC values from diffusion weighted imaging (DWI), SUV values from 18F-FDG PET/CT before
and after the first week of chemotherapy
4. Pre-treatment and interim follow up SUV values from 18F-FDG PET/CT
5. Post-treatment outcome and to understand the change of metabolites before and after
treatment and if possible, evaluate treatment outcome using the above imaging biomarkers
Aim 2:
In Stage 2 of this study, the investigators aim to recruit lymphoma patients with proven
relapse after treatment, to understand the changes of metabolites before and after treatment,
to compare the metabolite changes with Stage 1 patients and to evaluate the ability of
hyperpolarized 13C-labeled pyruvate from DNP MRS for detecting early treatment response in
these patients.